Compare ABRDN Physical Gold Shares ETF (SGOL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.52 (market cap $7.18B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: ABRDN Physical Gold Shares ETF and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SGOL | SYRE | |
|---|---|---|
Market Cap | $7.18B | $7.35B |
Volume | 3,881,341 | 1,624,631 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $108.92 |
52-Week Low | $37.54 | $22.18 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.63, down 0.13% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX showing sell signals. Support levels cluster around $39-40, while resistance is firm at $40. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices pressured by rising rates but supported by geopolitical tensions and strong Chinese imports.
The outlook remains cautious amid interest rate uncertainty, with potential for rebound if yields stabilize or conflict escalates. Risks include persistent inflation driving higher rates, while institutional analysts see mixed paths—some targeting $4,100 by year-end but others $5,000 by mid-2027. Investor sentiment is neutral to bearish short-term.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
